Ninety One North America’s AstraZeneca AZN Stock Holding History

Ninety One North America’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23.1M	Sell	123,512 -35,042	-22%	-$6.59M	1.08%	33
2026 Q1	$30.7M	Buy	+158,554	New	+$30.6M	1.38%	26

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Ninety One North America's AZN Position: Q2 2026 in Review

Ninety One North America reduced its AstraZeneca (AZN) stake by 22% in Q2 2026, selling an estimated $6.59M and leaving 123,512 shares worth $23.1M. The position accounts for 1.08% of the portfolio, ranked #33.

Ninety One North America first reported a position in AZN in Q1 2026 and has held it in 2 quarters since. The position peaked at $30.7M in Q1 2026. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Ninety One North America held 123,512 shares of AstraZeneca worth $23.1M as of Q2 2026.
Ninety One North America sold 35,042 AstraZeneca shares in Q2 2026, an estimated $6.59M.
AstraZeneca made up 1.08% of Ninety One North America's portfolio in Q2 2026, its #33 holding.
Ninety One North America first reported a position in AstraZeneca in Q1 2026 and has held it in 2 quarters since.
Ninety One North America's AstraZeneca position peaked at $30.7M in Q1 2026.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Ninety One North America's 13F filing for Q2 2026, filed 16 Jul 2026.